American Society of Hematology (ASH)

The American Society of Hematology (ASH) is a professional organization representing hematologists. It was founded in 1958. Its annual meeting is held in December of every year and has attracted more than 30,000 attendees. The society publishes the medical journal Blood, the most cited peer-reviewed publication in the field, which is available weekly in print and online, as well as the newly launched, online, peer-reviewed open-access journal, Blood Advances.
Researchers reported results of a population-based study examined sex, race, and age-stratified differences in incidence, mortality, and survival from 1973 to 2012 for 89,867 myeloma patients by using national epidemiologic data. Read More ›

Researchers presented results of patient-reported assessments of general health status as well as pain severity and interference using pooled data from 3 denosumab registrational trials that had enrolled patients with advanced cancers including multiple myeloma (MM). Read More ›

Researchers reported results of an analysis using national epidemiologic data and self-reported data from the Medicare Health Outcomes Survey that determined the prevalence of falls in older adults with newly diagnosed multiple myeloma (MM) and examined associations between falls and functional status, comorbidities, and self-reported health. Read More ›

Beth Faiman elaborates on her idea wish list of resources and tools that would help her to better manage patients on oral oncolytics. Read More ›

Updated findings from a study of ibrutinib plus venetoclax for patients with chronic lymphocytic leukemia (CLL), focusing specifically on the results of minimal residual disease testing. Read More ›

Criteria to assess presenting patterns of organ damage have not been extensively evaluated. Preliminary evidence suggests identifying these patterns could be useful in profiling organ dysfunction in avapritinib clinical trials. Read More ›

Gilteritinib plus azacitidine led to significantly higher composite complete remission rates but did not provide a survival advantage compared with azacitidine alone in patients with newly diagnosed FLT3mut+ AML ineligible for intensive induction chemotherapy. Read More ›

MRD status at the time of allogeneic stem-cell transplantation and the number of remissions prior to transplant were shown to be important independent prognostic factors in patients with AML. Read More ›

Cladribine has long been established as an efficient therapy in systemic mastocytosis and remains a valuable treatment option even as new therapies emerge. Read More ›

In the first-in-human phase 1/2 AUGMENT 101 study, SNDX-5613 demonstrated an acceptable safety profile and promising antileukemic activity in patients with heavily pretreated relapsed/refractory MLL-rearranged and NPM1-mutated acute leukemias. Read More ›

Page 6 of 44

Conference Correspondent Coverage is Brought to You by the Publishers of:
CONQUER: the patient voice
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
The Oncology Nurse–APN/PA
The Oncology Pharmacist
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications